Ligand Pharmaceuticals/$LGND
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
- Ticker
- $LGND
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 47
- Headquarters
- Jupiter, United States
- Website
- www.ligand.com
LGND Metrics
BasicAdvanced
$5.9B
32.15
$9.19
0.98
-
Price and volume
Market cap
$5.9B
Beta
0.98
52-week high
$326.63
52-week low
$175.89
Average daily volume
254K
Financial strength
Current ratio
34.521
Quick ratio
30.826
Long term debt to equity
1.168
Total debt to equity
1.164
Interest coverage (TTM)
21.23%
Profitability
EBITDA (TTM)
132.551
Gross margin (TTM)
81.20%
Net profit margin (TTM)
67.88%
Operating margin (TTM)
34.45%
Effective tax rate (TTM)
17.12%
Revenue per employee (TTM)
$6,180,000
Management effectiveness
Return on assets (TTM)
3.99%
Return on equity (TTM)
21.96%
Valuation
Price to earnings (TTM)
32.149
Price to revenue (TTM)
20.034
Price to book
6.13
Price to tangible book (TTM)
8.96
Price to free cash flow (TTM)
44.286
Free cash flow yield (TTM)
2.26%
Free cash flow per share (TTM)
6.673
Growth
Revenue change (TTM)
54.89%
Earnings per share change (TTM)
-329.98%
3-year revenue growth (CAGR)
17.32%
10-year revenue growth (CAGR)
12.68%
3-year earnings per share growth (CAGR)
80.56%
10-year earnings per share growth (CAGR)
-0.59%
What the Analysts think about LGND
Analyst ratings (Buy, Hold, Sell) for Ligand Pharmaceuticals stock.
Analyst projections of the future price of Ligand Pharmaceuticals stock.
Bulls say / Bears say
Royalty revenue rose 32% year on year to $48.0 million in Q2, helping lift total revenue by 34%. Ligand raised the low end of its 2026 adjusted EPS guidance to $9.00, supporting the case that commercial royalties are translating into earnings growth. (Ligand Pharmaceuticals)
The completed XOMA acquisition adds more than 120 assets, including seven commercial programmes, and broadens Ligand’s royalty base. Management expects it to add about $1.50 per share to adjusted EPS in 2027, offering a sizeable source of near-term growth if integration goes to plan. (Ligand Pharmaceuticals)
FDA approval of Filspari for FSGS gives the drug a second rare-kidney-disease indication, where it is the first and only approved treatment. Ligand earns a 9% royalty on worldwide sales, so broader use could add to its royalty stream. (Ligand Pharmaceuticals)
Ligand still depends on the sales performance of partner products, and results can diverge across the portfolio: Kyprolis sales fell 17% year on year in Q2. Weaker performance from a major product could offset growth elsewhere. (The Motley Fool)
Captisol sales fell to $8.0 million in Q2 from $8.3 million a year earlier, and first-half sales were down to $16.6 million from $21.7 million. The full-year target also depends on a back-end-loaded recovery, with most remaining sales expected in Q4. (StockTitan, The Motley Fool)
Pipeline assets are uncertain sources of future royalties: management pushed the expected volixibat PSC regulatory submission into the first half of 2027 while continuing discussions with the FDA. Further delays or clinical setbacks could defer the growth expected from these programmes. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
LGND Financial Performance
Revenues and expenses
LGND Earnings Performance
Company profitability
Upcoming events
No upcoming events
LGND News
AllArticlesVideos
Funds containing LGND
AllUSDEURGBP
Fund name | Fund size | $LGND weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.61% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.61% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.61% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.40% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.40% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.